Diagnostic hapten-carrier conjugates BSA-Homocysteine (HCY), OVA-Homocysteine (HCY), KLH-Homocysteine (HCY) for cardiovascular diseaseHCYdetection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
Product Details
Homocysteine is an amino acid. Vitamins B12, B6 and folate break down homocysteine to create other chemicals your body needs. High homocysteine levels may mean you have a vitamin deficiency. Without treatment, elevated homocysteine increases your risks for dementia, heart disease and stroke.Genemedi produces core diagnostic ingredients for test of cardiovascular disease and related syndrome.
GeneMedi offers Diagnostic hapten-carrier conjugates BSA-Homocysteine (HCY), OVA-Homocysteine (HCY), KLH-Homocysteine (HCY) for cardiovascular disease HCY detection in Competitive immunoassay validation (Competitive ELISA), Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT. All the antibodies and antigens for cardiovascular disease test are suitable for in functional ELISA, and other immunoassays in dignostics.
Product Description
|
Cat No.
|
GMP-SMT-HCY-Ag-Ab
|
|
Product Name
|
BSA-Homocysteine (HCY) / OVA-Homocysteine (HCY)
|
|
Expression platform
|
Synthetic
|
|
Bioactivity validation
|
Homocysteine (HCY) antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in HCY level test of Cardiovascular disease (dementia, heart disease and stroke.) and related syndrome evaluation
|
|
Products description
|
Competitive immunoassay-validated hapten-carrier conjugates BSA-Homocysteine (HCY) / OVA-Homocysteine (HCY) is Synthetic.
|
|
Purity
|
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA), ELISA, Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
|
Cat No.
|
GMP-SMT-HCY-Ag-Ab
|
|
Product Name
|
Anti-human Homocysteine (HCY) mouse monoclonal antibody (mAb)
|
|
Expression platform
|
Hybridoma
|
|
Isotypes
|
Mouse IgG
|
|
Bioactivity validation
|
Homocysteine (HCY) antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other Homocysteine (HCY) antibodies in HCY level test of Cardiovascular disease (dementia, heart disease and stroke.) and related syndrome evaluation.
|
|
Tag
|
mFc
|
|
Products description
|
Anti-human Homocysteine (HCY) mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by hybridoma technology.
|
|
Specics
|
mouse
|
|
Purity
|
Purity: ≥95% （SDS-PAGE）
|
|
Application
|
Competitive immunoassay validation (Competitive ELISA),Lateral flow immunoassay (LFIA),colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA),turbidimetric inhibition immuno assay (TINIA) and Immunonephelometry.
|
|
Formulation
|
Lyophilized from sterile PBS, PH 7.4
|
|
Storage
|
Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.
|
Diagnostic antibodies and antigens for Epilepsy-related valproate (VPA) toxicity testing: Sodium valproate (VPA)
Valproate is a commonly used antiepileptic drug for the treatment of epilepsy and seizures. It is safe for use in both adults and children more than three years of age. Valproate toxicity can occur both accidentally and intentionally. Acute valproate overdose usually presents with CNS depression/encephalopathy, electrolyte abnormalities such as hypernatremia, elevated transaminase levels, hyperammonemia, and hepatoxicity. In patients with a severe overdose of valproate, patients can present with hypotension, tachycardia, respiratory depression, metabolic acidosis, cerebral edema, and valproate-related hyperammonemic encephalopathy which may progress to coma and death. GENEMEDI developed the Gastrin-17 (G-17) antigens and antibodies for the diagnosis of valproate toxicity based on ELISA, Lateral flow immunoassay (LFIA), colloidal gold immunochromatographic assay, Chemiluminescent immunoassay (CLIA), turbidimetric inhibition immuno assay (TINIA), immunonephelometry and POCT.
